These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

26 related articles for article (PubMed ID: 21733123)

  • 1. Non-Adherence in Adult Male Patients with Community-Acquired Pneumonia: Relative Forgiveness of Amoxicillin versus Respiratory Fluoroquinolones.
    Carral N; Lukas JC; Estradé O; Jauregizar N; Morillas H; Suárez E
    Antibiotics (Basel); 2023 May; 12(5):. PubMed ID: 37237741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model.
    Jadhav SB; Crass RL; Chapel S; Kerschnitzki M; Sasiela WJ; Emery MG; Amore BM; Barrett PHR; Watts GF; Catapano AL
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(6):578-586. PubMed ID: 34448822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circadian Clock Regulation on Lipid Metabolism and Metabolic Diseases.
    Pan X; Mota S; Zhang B
    Adv Exp Med Biol; 2020; 1276():53-66. PubMed ID: 32705594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the Effect of Statins and Patient Adherence in Atherosclerosis via a Quantitative Systems Pharmacology Model Using a Novel, Hybrid, and Multi-Scale Approach.
    Pichardo-Almarza C; Diaz-Zuccarini V
    Front Pharmacol; 2017; 8():635. PubMed ID: 28955237
    [No Abstract]   [Full Text] [Related]  

  • 5. From PK/PD to QSP: Understanding the Dynamic Effect of Cholesterol-Lowering Drugs on Atherosclerosis Progression and Stratified Medicine.
    Pichardo-Almarza C; Diaz-Zuccarini V
    Curr Pharm Des; 2016; 22(46):6903-6910. PubMed ID: 27592718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using a Systems Pharmacology Approach to Study the Effect of Statins on the Early Stage of Atherosclerosis in Humans.
    Pichardo-Almarza C; Metcalf L; Finkelstein A; Diaz-Zuccarini V
    CPT Pharmacometrics Syst Pharmacol; 2015 Jan; 4(1):e00007. PubMed ID: 26225221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
    Robinson JG; Davidson MH
    Expert Rev Cardiovasc Ther; 2006 Jul; 4(4):461-76. PubMed ID: 16918265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
    Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized crossover study to evaluate LDL-cholesterol lowering effect of a generic product of simvastatin (Unison Company) compared to simvastatin (Zocor) in hypercholesterolemic subjects.
    Assawawitoontip S; Wiwanitkit V
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S118-24. PubMed ID: 12188401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal low-density lipoprotein cholesterol lowering--morning versus evening statin administration.
    Plakogiannis R; Cohen H
    Ann Pharmacother; 2007 Jan; 41(1):106-10. PubMed ID: 17200427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A population pharmacokinetic-pharmacodynamic model for simvastatin that predicts low-density lipoprotein-cholesterol reduction in patients with primary hyperlipidaemia.
    Kim J; Ahn BJ; Chae HS; Han S; Doh K; Choi J; Jun YK; Lee YW; Yim DS
    Basic Clin Pharmacol Toxicol; 2011 Sep; 109(3):156-63. PubMed ID: 21426490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study.
    Rump LC; Baranova E; Okopien B; Weisskopf M; Kandra A; Ferber P
    Clin Ther; 2008 Oct; 30(10):1782-93. PubMed ID: 19014834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of dosing time, variable compliance and circadian low-density lipoprotein production on the effect of simvastatin: simulations from a pharmacokinetic-pharmacodynamic model.
    Wright DF; Pavan Kumar VV; Al-Sallami HS; Duffull SB
    Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):494-8. PubMed ID: 21733123
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.